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Abstract   
We previously characterized the morphological characteristics of MPM cells with 9p21 
homozygous deletion (HD) using a combination of the virtual microscopy and fluorescence in 
situ hybridization (FISH). In this study, we investigated whether MPM cells with 
BRCA1-associated protein 1 (BAP1) loss show the same morphological characteristics 55 
identified in MPM cells with 9p21 HD. MPM cells with either BAP1 loss detected by 
immunocytochemistry (ICC) or 9p21 HD detected by FISH were identified via virtual 
microscopy prior to ICC or FISH, followed by analysis and quantification of their 
morphological characteristics. MPM cells with BAP1 loss or 9p21 HD exhibited significantly 
more frequent cell-in-cell engulfment, multinucleation, and larger multicellular clusters 60 
composed of more than 10 cells than reactive mesothelial cells. In conclusion, MPM cells 
with BAP1 loss or 9p21 HD share similar cytological features, indicating that the same 
morphological criteria can be used to detect MPM cells harboring such genetic aberrations. 
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Introduction 
Malignant Pleural Mesothelioma (MPM) is a highly aggressive malignancy associated 
with asbestos exposure. As a result of heavy industrial use of asbestos in the recent past, the 
disease incidence in Japan is expected to rise over the next one or two decades.1 Poor 80 
prognosis associated with the disease is related, at least in part, to difficulties in diagnosis at 
early stages. Because 54–89% of MPM patients present initially with pleural effusion, 
cytologic analysis is the primary diagnostic approach for most patients.2, 3 Detection of 
mesothelioma cells in effusion smear cytology is thus critical for early diagnosis. 
Immunohistochemistry (IHC) is useful in distinguishing MPM from metastatic tumor cells in 85 
the pleura. However, distinguishing mesothelioma cells from reactive mesothelial cells 
(RMC) remains challenging. A variety of markers, including desmin, epithelial membrane 
antigen (EMA), glucose transporter-1 (GLUT-1), and CD146, have been evaluated in both 
tissue and cytological samples to discriminate MPM cells from RMC, but these are not useful 
in an individual case.4-8 90 
Recent studies have revealed the usefulness of two new markers: 1) homozygous 
deletion (HD) of the 9p21 region, including the p16 gene, detected by fluorescence in situ 
hybridization (FISH)3, 9-20, and 2) loss of nuclear expression of BRCA1-associated protein 1 
(BAP1), detected by IHC.18, 20-31 While sensitivity for detecting these markers is not high, they 
do provide high specificity (100%). Detection of BAP1 using IHC and 9p21 HD using FISH 95 
provide candidate approaches for discriminating between MPM cells and RMC, as these 
techniques can be applied to effusion smears.21, 23, 24, 28, 30, 31  
Previously, we analyzed and reported the morphological characteristics of 
mesothelioma cells with 9p21 HD using a combination of virtual microscopy and 9p21 
FISH.15, 17 Compared with RMC that retained the 9p21 region, MPM cells with 9p21 HD 100 
exhibited significantly more frequent cell-in-cell engulfment, multinucleation (with 2 or more 
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nuclei), and larger multicellular, berry-like clusters composed of more than 10 cells. These 
characteristics were the same as those included in the cytological criteria proposed for 
diagnosing MPM by the International Mesothelioma Interest Group (IMIG).5-7 It remains 
unclear, however, whether loss of BAP1 in MPM cells is also associated with these 105 
characteristic morphological changes. The objective of the current study was to determine 
whether the same morphological criteria could be used to identify MPM cells with BAP1 loss 
in addition to MPM cells with 9p21 HD. For this purpose, we investigated and compared 
morphological changes in MPM cells associated with BAP1 loss with those associated with 
9p21 HD, using our previously developed methodology. 110 
 
Materials and Methods 
All study procedures were approved by the Fukuoka University Hospital Institutional 
Review Board, which approved the study protocol (approval number 11-7-11) and allowed a 
waiver of informed consent for the study. Use of redundant tissues and cells is allowed under 115 
the standard patient treatment agreement at Fukuoka University Hospital, provided no patient 
objections are expressed.   
Case Selection and Smear Preparations 
This study included cytological preparations obtained from pleural effusions in 43 
patients with MPM (32 males and 11 females; age range: 55-95 years [mean, 72.1 years]) and 120 
in 45 patients with RMC associated with tuberculosis, pneumonia, cardiovascular disease, 
lung cancer, and bullae (30 males and 15 females; age range: 36-95 years [mean, 68.6 years]). 
The MPM cases included 40 epithelioid and 3 biphasic mesotheliomas. All 88 cases were 
derived from the pleural lesion file of the Department of Pathology, Fukuoka University 
Hospital, and included consultation cases between 2005 and 2016. The diagnosis of MPM 125 
was confirmed in tissue samples, and the histologic tumor subtypes were identified using the 
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World Health Organization classification32. Mesothelial origin of tumors was determined by 
IHC, using a combination of calretinin, podoplanin (D2-40), cytokeratin 5/6, and Wilms 
tumor 1 (WT-1) staining as positive mesothelial markers, and thyroid transcription factor 1 
(TTF-1), claudin-4, and carcinoembryonic antigen (CEA) as negative markers. All smear 130 
preparations were fixed in 95% ethanol, stained according to Papanicolaou staining protocol, 
digitized using a virtual microscope system (NanoZoomer 2.0-HT, Hamamatsu Photonics, 
Hamamatsu, Japan), and then subjected to BAP1 immunocytochemistry (ICC) and 9p21 FISH 
analyses. 
 135 
Immunocytochemistry (ICC) of BAP1 
ICC for BAP1 was performed on an automated Dako Autostainer Link 48 platform 
using the DAKO EnVision Plus Kit (Agilent Technologies Company, Glostrup, Denmark). 
Briefly, Papanicolaou-stained smear preparations were treated in xylene overnight to remove 
the mounting medium, followed by rehydration in descending alcohol dilutions and heating at 140 
95 °C in pH 9.0 Tris-EDTA buffer for 10 minutes using water bath to retrieve epitopes. After 
blocking the endogenous peroxidase activity using a blocking reagent (Dako EnVision Plus 
Kit) for five minutes at room temperature (RT), slides were incubated with mouse monoclonal 
anti-human BAP1 antibody (clone C-4; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 
1:200 dilution) at RT for 30 minutes. Immunoreacted cells were visualized with 145 
3,3’-diaminobenzidine, and nuclei were counterstained with Mayer’s hematoxylin. BAP1 
staining was evaluated by a cytologist and a pathologist and nuclear BAP1 staining was 
scored as loss or retained. Cytoplasmic staining was considered nonspecific, and positive 
nuclear staining in non-neoplastic cells was noted as an internal positive control. The cutoff 
value for loss of BAP1 was set at 50%, as described previously.18, 29, 31 150 
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FISH Assay 
9p21 FISH was performed on smears of decoversliped Papanicolaou-stained slides 
using Vysis LSI CDKN2A SpectrumOrange/CEP9 SpectrumGreen Probes (Abbott Japan, 
Tokyo, Japan). Briefly, smear slides were treated with 2 × saline-sodium citrate buffer (SSC) 155 
containing 0.3% Tween 20 (SSC-0.3T; Sigma-Aldrich), incubated in pretreatment solution 
(0.01M citrate buffer, pH 6.0) at 80 ˚C for 15 minutes, and then digested using pepsin solution 
(0.3%-pepsin/0.01N-HCl; Sigma-Aldrich, P-6887) at 37 ˚C for 15 minutes. After refixation in 
10% neutral buffered formalin at RT for five minutes, the preparations were treated in 2 × 
SSC-0.3T at 45 ˚C for 30 minutes, dehydrated in ethanol, dried, and exposed to the probes. 160 
The probes and preparations were denatured at 80 ˚C for 10 minutes in the probe solution 
provided (Abbott Japan), followed by hybridization at 37 ˚C for 24 hours in a ThermoBrite 
unit (Abbott Japan). The preparations were washed in 2 × SSC-0.3T at 72 ˚C for 3–5 minutes 
and in 2 × SSC containing 0.1% Tween 20 at RT for 3–5 minutes. The nuclei were 
counterstained using 4’, 6-diamidino-2-phenylindole (DAPI) in the antifade reagent (Vector 165 
Laboratories, Burlingame, CA, USA). Analyses were performed using a fluorescence 
microscope (AxioImager Z1; Carl Zeiss Microimaging, Jena, Germany) and the Isis analysis 
system (Metasystems, Altlussheim, Germany) equipped with filter sets with single- and 
dual-band exciters for SpectrumGreen, SpectrumOrange, and DAPI (UV, 360 nm). 
Lymphocytes or histiocytes in each smear served as internal controls. HD was defined as a 170 
lack of both 9p21 signals. The percentage of cells with 9p21 HD detected by FISH was 
determined by evaluating at least 200 mesothelial cells per sample. The cutoff value for HD of 
9p21 as detected by FISH was set at 10%, as described previously.15-17  
Morphological analysis  
MPM cells with BAP1 loss (detected by ICC) and MPM cells with 9p21 HD (detected 175 
by FISH) were identified on the Papanicolaou-stained smears of MPM that had been recorded 
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using a virtual microscope system. Similarly, RMC without BAP1 loss and RMC retaining the 
9p21 locus were identified in Papanicolaou-stained smears of non-mesothelioma cases. We 
analyzed the morphological characteristics of MPM cells with BAP1 loss and/or 9p21 
HD-positive MPM cells. We compared these characteristics to those in RMC without BAP1 180 
loss or 9p21 deletion. The frequency of cell-in-cell engulfment (with or without cytoplasmic 
protrusion [i.e., hump formation]), multinucleate cells, and berry-like or papillary cell 
aggregates composed of >10 cells (i.e., cellular spheres or morules) were quantified. At least 
200 mesothelial cells per slide were evaluated. We set the cutoff values which were calculated 
as the mean percentage + 3 standard deviations (SDs) of frequency in RMC without BAP1 185 
loss or 9p21 HD as previously described.15 
Statistical Analysis 
Statistical comparison of cytological features between MPM cells and RMC was 
performed using the Wilcoxon test. A p value < 0.05 was considered statistically significant. 
All statistical evaluations were performed with JUMP 10 software (SAS Institute, Cary, NC). 190 
 
Results 
Results of BAP1 ICC and 9p21 FISH in effusion smears 
Table 1 shows the results of BAP1 ICC and 9p21 FISH in effusion smears. Twenty-one 
of the 43 MPM samples (48.8%) showed a loss of nuclear BAP1 expression. All RMC 195 
(non-mesothelioma samples) in which BAP1 ICC was performed showed retention of nuclear 
BAP1 expression (17/17 samples). Of the 43 MPM samples that were analyzed by FISH, 21 
cases (48.8%) showed 9p21 HD. None of the 28 RMC cases in which 9p21 FISH was 
performed, showed 9p21 HD. Seven of the 43 MPM cases (16.2 %) showed a loss of nuclear 
BAP1 expression as well as 9p21 HD, and eight cases (18.6 %) had neither BAP1 loss nor 200 
9p21 HD. Fourteen MPM cases (32.6%) showed either BAP1 loss or 9p21 HD. Based on 
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these results, ICC for BAP1 detection and FISH for detection of 9p21 HD were each 
characterized by a specificity of 100% and a sensitivity of 48.8% for differentiation of MPM 
from RMC. The combination of the two approaches yielded an increased sensitivity of 81.4%. 
Morphology of BAP1 loss or p16 HD positive mesothelioma cells 205 
     We analyzed cellular morphology in MPM cases with BAP1 loss alone (n=14, 12 males 
and 2 females; age range: 57-82 years [mean, 73.3 years]) or in those with 9p21 HD alone 
(n=14, 10 males and 4 females; age range: 58-95 years [mean, 74.1 years]). As a control 
comparison, morphological characteristics were examined in smears of non-mesothelioma 
cases, in which ICC was used to detect BAP1 expression (n=17, 10 males and 7 females; age 210 
range: 44-89 years [mean, 67.7 years]) or FISH was used to detect the 9p21 locus (n=28, 19 
males and 9 females; age range: 36-95 years [mean, 69 years]). The cytologic features of 
mesothelioma cells with BAP1 loss and those with 9p21 HD are shown in Figure 1 and 2, 
respectively. 
MPM cells with BAP1 loss demonstrated significantly more frequent cell-in-cell 215 
engulfment (with or without a hump-like appearance) than RMC in which BAP1 expression 
was retained (Figure 1A-B and 3A). This feature was seen in 13.0 ± 7.1% of MPM cells 
with BAP1 loss in contrast to 3.3 ± 1.4% of RMC in which BAP1 expression was retained. 
Ten cases of MPM with BAP1 loss (10/14, 71.4%) showed cell-in-cell engulfment at a rate 
that was higher than a cutoff value (7.5%) calculated as the mean frequency of cell-in-cell 220 
engulfment found in RMC + 3SDs. Whereas all RMC vases remained below the cutoff values. 
(100% specificity). Similarly, MPM cells with 9p21 HD also exhibited significantly more 
frequent cell-in-cell engulfment (17.4 ± 10.6% of cells) than RMC that retained the 9p21 
locus (3.5 ± 2.5% of cells; Figure 2A-B and 3B). Moreover, ten cases of MPM with 9p21 
HD (10/14, 71.4%) showed cell-in-cell engulfment at a rate that was higher than the 225 
calculated cutoff value (11%). Whereas all RMC vases remained below the cutoff values. 
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(100% specificity). 
Binucleation and multinucleation (> 2 nuclei) were also significantly more frequent in 
MPM cells with BAP1 loss or MPM cells with 9p21 HD relative to control RMC. 
Binucleation was observed in 27.5 ± 6.7% vs 10.5 ± 3.1% of MPM cells with BAP1 loss 230 
vs RMC, respectively. Similarly, multinucleation was observed in 7.3 ± 2.9% vs 1.3 ± 
1.1% of cells, respectively. A similar difference was noted in comparing MPM cells with 9p21 
HD vs RMC. Binucleation was present in 26.6 ± 9.2% vs 9.8 ± 3.9% of cells, and 
multinucleation was present in 11.0 ± 7.0% vs 1.0 ± 0.9% of cells, respectively (Figure 
1C-D, 2C-D and 4). The cutoff values for multinucleation were much lower than those for 235 
binucleation for both BAP1 loss and 9p21 HD (19.8% vs 4.6% for BAP1 loss; 21.5% vs 3.7% 
for 9p21 HD). Twelve MPM cases with BAP1 loss (12/14, 86%) showed a rate of 
multinucleation higher than the cutoff value (4.6%), while 11 cases of MPM with 9p21 HD 
(11/14, 78%) showed a rate of multinucleation higher than the cutoff value (3.7%). All RMC 
cases were below the cutoff values. 240 
Multicellular ball or berry-like clusters of mesothelial cells were also more often found 
in MPM cells (Figure 1E-F, 2E-F and 5). These multicellular clusters were three-dimensional, 
with many overlapping cells. BAP1 loss could be evaluated by ICC even in these cell clusters. 
However, determination of 9p21 HD by FISH could be achieved only at the periphery of the 
clusters. Based on this limitation, statistical analysis of 9p21 HD in multicellular clusters was 245 
performed only in 9p21 HD-predominant MPM cases, in which more than 90% of cells were 
9p21 HD positive (n=12). Multicellular, three-dimensional cell clusters composed of 10-99 
cells were found significantly more frequently in MPM cells with loss of BAP1 expression 
(11.2 ± 10.1%) and MPM cells with 9p21 HD (16.1 ± 12.4%) relative to RMC in which 
BAP1 expression was retained (0.7 ± 1.1%) and RMC in which the 9p21 locus was retained 250 
(1.2 ± 1.5%). In analyzing multicellular clusters composed of 10-99 cells, ten MPM cases 
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with BAP1 loss (10/14, 71%) and nine cases of MPM with 9p21 HD (9/12, 75%) showed 
cluster rates over the cutoff values of 4.0% and 5.7%, respectively. All RMC cases were 
below the cutoff values. In addition, clusters of more than 100 cells were found in 11 MPM 
cases with BAP1 loss (11/14, 78.6%) and ten MPM cases with 9p21 HD (10/12, 83%). In 255 
contrast, these clusters were not found in any RMC cases in which BAP1 expression was 
retained, and were found in only two RMC cases in which the 9p21 locus was retained (2/28, 
7.1%). Moreover, clusters seen in RMC cases were frequently composed of flat, sheet-like 
monolayers, rather than the three-dimensional, overlapping clusters typically formed by MPM 
cells.   260 
 
Discussion 
In the current study, we demonstrated that loss of BAP1 in MPM results in the similar 
morphological characteristics as found in MPM cells with the 9p21 HD. Our findings indicate 
that MPM cells with either BAP1 loss or 9p21 HD can be detected using the same 265 
morphological criteria. Furthermore, these findings suggest that distinct genetic alterations 
lead to convergent morphological changes. These results show that a number of cellular 
morphological features, including cell-in-cell engulfment, multinucleation, and berry-like 
clusters, are not exclusively dependent on either BAP1 loss or 9p21 HD. 
BAP1 is a nuclear ubiquitin hydrolase that regulates gene expression, transcription, and 270 
DNA repair, and functions as a classical tumor suppressor. BAP1 mutations are thought to be 
driver mutations for the development of MPM.27, 33, 34 Mutations in the BAP1 gene is observed 
in 56–81% of epithelioid mesotheliomas,17 which is a higher frequency than that observed in 
either biphasic (45–60%) or sarcomatoid mesothelioma (15–63%)20, 27. Mutations in the BAP1 
gene lead to loss of BAP1 expression in cell nuclei detected by IHC/ICC in 88-100% of 275 
mesotheliomas.35 This enabled us to investigate and analyze the cellular morphological 
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characteristics associated with BAP1 loss. 
A number of studies (including a publication from our group) in which tissue and cell 
block samples were analyzed, have shown that assaying for both loss of BAP1 and 9p21 HD 
substantially increased test sensitivity, leading to increased confidence in MPM diagnosis and 280 
in differentiation of MPM from reactive mesothelial hyperplasia.18, 20, 21, 24, 28, 29 In the present 
study, combining the two assays yielded a sensitivity of 81.4%, which was higher than that 
achieved with either BAP1 IHC alone (48.8%) or 9p21 FISH alone (48.8%). 
In this study, we demonstrated that BAP1 ICC can be applied to Papanicolaou-stained 
effusion smears as proposed previously.30 Relative to FISH, use of ICC to detect BAP1 285 
allows target cells to be identified more easily, because cells can be easily observed using a 
light microscope. Moreover, the evaluation of BAP1 loss using ICC is possible even in 
overlapping clusters of cells. In contrast, the limitations of fluorescence microscopy make 
identification of target cells within such clusters difficult using FISH-based assays, in which 
identification of 9p21 HD can generally be achieved only at the periphery of overlapping cell 290 
clusters. Caution is warranted, however, in using ICC to assay for loss of BAP1 nuclear 
staining. In particular, good internal controls are necessary, to ensure that robust staining is 
achieved when BAP1 protein is present. In our studies, we assessed BAP1 loss in tumor cells 
only when clear staining in background lymphocytes or histiocytes was present and could 
serve as an internal positive control. 295 
Cytomorphological features of MPM cells have been characterized in numerous studies, 
but the cytologic diagnosis of MPM can still present significant challenges. The 
cytomorphological features found in MPM cells, RMCs, and metastatic carcinoma cells 
sometimes exhibit substantial overlap. Moreover, MPM cells and RMC are typically both 
present in effusion smears, making it difficult to detect morphological characteristics essential 300 
for the diagnosis of MPM. IMIG guidelines, which provide specific guidance for the 
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cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma, have also 
been endorsed by the International Academy of Cytology and the Papanicolaou Society of 
Cytopathology.5-7 The guidelines specify ten cytomorphological criteria for identifying 
malignant mesothelioma, including the presence of: 1) a highly cellular sample; 305 
2) mesothelial cells that are significantly larger than RMC; 3) papillary clusters with a smooth 
surface or berry-like clusters with a scalloped surface; 4) acidophilic extracellular matrix 
cores; 5) macro nucleoli; 6) protrusions from the cell membrane or blebbing; 7) a prominent 
degree of cell-within-cell arrangement; 8) multinucleated giant cells and pyknotic eosinophilic 
cells; and 10) vacuoles overlapping the nuclei of May-Grünwald Giemsa (MGG) stained cells. 310 
The morphological characteristics of MPM cells with BAP1 loss or 9p21 HD observed in our 
study meet the criteria for mesothelioma diagnosis proposed by the guidelines. 
The frequency with which morphological characteristics suggestive of MPM occur can 
provide additional important information that strengthens confidence in a diagnosis of 
mesothelioma. In the present study, we analyzed the frequency of occurrence of 315 
morphological characteristics associated with MPM cells, and calculated cutoff values for 
each characteristic associated with BAP1 loss or 9p21 HD. These cutoff values may be useful 
for daily practice of MPM diagnosis. 
The current study has a few limitations. First, we selected the cellular characteristics 
that had been frequently found in 9p21 HD-positive MPM cells15 as study items. because we 320 
intended to know the difference or similarity between MPM cells with BAP1 loss or 9p21 HD. 
Therefore, other morphological criteria described in the IMIG guidelines were not examined. 
Further studies about these criteria will be needed in the future. Second, it is important to 
compare the cytomorphological parameters between BAP1 loss and BAP1 retained cases or 
between 9p21 HD-positive and negative cases. However, it was technically difficult to pick up 325 
BAP1 retained or 9p21 HD-negative MPM cells accurately, since smears almost always 
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include both MPM and RMC. Thus, in this study, we identified MPM cells by detecting BAP1 
loss or 9p21 HD using ICC or FISH, respectively, and performed cytomorphological analysis 
between the MPM cells with loss/deletion and RMC without loss/deletion. 
In the present study, we distinguished MPM cells from RMC by detecting either loss of 330 
BAP1 or 9p21 HD. In addition, we examined morphological characteristics of MPM cells that 
had either loss of BAP1 expression, or 9p21 HD, and found that their morphological 
characteristics were similar. These findings suggest that the same morphological criteria can 
be applied for screening or detecting MPM cells with either loss of BAP1 or 9p21 HD. The 
three morphological characteristics observed in our study, cell-in-cell engulfment, 335 
multinucleation and larger multicellular clusters, are included in the IMIG cytomorphological 
criteria for the diagnosis of malignant mesothelioma. Based on the cutoff values to favor 
diagnosis of MPM in the current study, sensitivities for detecting MPM cells with either BAP1 
loss or 9p21 HD using the three morphological characteristics were 71.4%, 78-86% and 
71-83%, respectively. A combination of these characteristics may increase the sensitivities. 340 
Moreover, their specificities were all 100% since values for RMC were below the cutoff value. 
Thereby, these lines of evidence support the usefulness of the guideline criteria to detect MPM 
cells with either of the two genetic changes. To our knowledge, this study is the first to 
characterize the morphological characteristics of MPM cells that have lost nuclear expression 
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Figure Legends 
 
Figure 1.  
Micrographs show cytologic features of mesothelioma cells with BAP1 loss after 525 
immunocytochemistry (A, C, and E) and Papanicolaou-stained smears (B, D, and F). The 
same cells are shown in image pairs: (A) and (B), (C) and (D), and (E) and (F). Note the 
cell-in-cell engulfment with or without hump formation (A and B), multinucleation (C and D), 
and berry-like multicellular clusters (E and F). Nuclear staining for BAP1 was negative in 
mesothelioma cells but positive in cell nuclei of adjacent inflammatory cells.  530 
 
Figure 2.  
Micrographs show cytologic features of mesothelioma cells with 9p21 HD after FISH (A, C, 
and E) and Papanicolaou-stained smears (B, D, and F). The same cells are shown in image 
pairs: (A) and (B), (C) and (D), and (E) and (F). Note the cell-in-cell engulfment with or 535 
without hump formation (A and B), multinucleation (C and D), and berry-like multicellular 
clusters (E and F). 
 
Figure 3. 
Frequency of cell-in-cell engulfment in MPM cells with BAP1 loss or 9p21 HD vs. RMC with 540 
BAP1 expression or retention of the 9p21 locus.  
(A) Comparison of MPM cells with BAP1 loss (14 cases) vs. RMC with nuclear BAP1 
expression (17 cases).  
(B) Comparison of MPM cells with 9p21 HD (14 cases) vs. RMC in which the 9p21 locus 
was retained (28 cases).  545 
HD; homozygous deletion, RMC; reactive mesothelial cell. 
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Figure 4. 
Frequency of multinucleated cells in MPM cells with BAP1 loss or 9p21 HD vs. RMC with 
BAP1 expression or retention of the 9p21 locus.  550 
(A) Comparison of MPM cells with BAP1 loss (14 cases) vs. RMC with nuclear BAP1 
expression (17 cases). 
(B) Comparison of MPM cells with 9p21 HD (14 cases) vs. RMC in which the 9p21 locus 
was retained (28 cases).  
HD; homozygous deletion, RMC; reactive mesothelial cell. 555 
 
Figure 5. 
Frequency of multicellular clusters in MPM cells with BAP1 loss or 9p21 HD vs. RMC with 
BAP1 expression or retention of the 9p21 locus.  
(A) Comparison of MPM cells with BAP1 loss (n=14) vs. RMC with nuclear BAP1 560 
expression (n=17).  
(B) The number of multicellular clusters was classified according to their size in smears from 
mesothelioma cases (n=12) in which 9p21 HD predominated (> 90%) vs. RMC with normal 
9p21 pattern (n=28).  
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 - / -  + / -  - / +  + / +
MPM 43 21/43 (48.8) 21/43 (48.8) 8 (18.6) 14 (32.6) 14 (32.6) 7 (16.2)
RMC 45 0/17 (0) 0/28 (0) 17/28 (100) * 0 0 0
BAP1 loss indicates loss of BAP1 expression in nuclei detected by immunocytochemistry.
9p21  HD indicates homozygous deletion (HD) of the 9p21 region detected by fluorescence in situ
hybridization (FISH)
* All RMC in which BAP1 immunocytochemistry was performed retained nuclear BAP1 expression
(17/17 samples) and none of the 28 RMC cases in which 9p21 FISH was performed, showed 9p21 HD
(28/28 samples)
MPM, malignant pleural mesothelioma cases; RMC, reactive mesothelial cells cases
TABLE 1. Results of BAP1 loss and 9p21  homozygous deletion on effusion smears
Cell Type BAP1  loss (%) 9p21 HD (%)
BAP1 loss / 9p21 HD (%)
Total
 
 
